A randomised, double-blind, placebo-controlled, parallel-group trial of Vitamin D supplementation compared to placebo in people presenting with their First Episode of psychosis Neuroprotection Design (DFEND) | C4C

We hypothesise that optimal vitamin D status could be neuroprotective, (and thus prevent further neuron degeneration in those with first episode psychosis (FEP). This project aims to determine whether the addition of 120,000 IU monthly of vitamin D (cholecalciferol) supplement to standard treatments is more efficacious than placebo in improving symptom outcomes at six month follow-up in those with First Episode Psychosis.